HC Wainwright & Co. Maintains Buy on Biodesix, Lowers Price Target to $34
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and lowers the price target from $38 to $34.
HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and lowers the price target from $38 to $34.